EUCTR2015-000148-40-GB进行中(未招募)1 期
Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of idiopathic PD
- •Modified Hoehn and Yahr stage = 3.0 in the ON medication state
- •Age 40-90 years
- •On dopaminergic treatment with wearing-off phenomenon
- •Able to comply with study protocol and willing to attend necessary study visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 48
排除标准
- •Diagnosis or suspicion of other cause for parkinsonism
- •Known abnormality on CT or MRI brain imaging considered to be causing symptoms or signs of neurological dysfunction, or considered likely to compromise compliance with study protocol
- •Concurrent dementia defined by MoCA score <21
- •Concurrent severe depression defined by MADRS score >31
- •Prior intracerebral surgical intervention for PD including deep brain stimulation, lesional surgery, growth factor administration, gene therapy or cell transplantation
- •Already actively participating in a research study that might conflict with this trial
- •Prior or current use of statins as a lipid lowering therapy
- •Intolerance to statins
- •Untreated hypothyroidism
- •End stage renal disease (creatinine clearance <30 mL/min) or history of severe cardiac disease (angina, myocardial infarction or cardiac surgery in preceding two years)
- •eGFR <30 mL/min
- •History of alcoholism or liver impairment
- •Creatine kinase (CK) >1.1 x upper limit of normal (ULN)
- •Aspartate transaminase (AST) or alanine transaminase (ALT) >1.1 x ULN
- •Females who are pregnant or breast feeding or of child-bearing potential and unwilling to use appropriate contraception methods whilst on trial treatment
- •Currently taking any medication contraindicated with simvastatin use
- •Any requirement for statin use
- •Regular participation in endurance or high-impact sports
- •Unable to abstain from consumption of grapefruit-based products
研究者
相似试验
已完成
不适用
Simvastatin as a neuroprotective treatment for moderate Parkinson's diseaseParkinson's diseaseTopic: Dementias and neurodegenerationSubtopic: Parkinson’s DiseaseDisease: Parkinson's diseaseNervous System DiseasesISRCTN16108482Plymouth Hospitals NHS Trust235
招募中
1 期
PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter studyCTIS2024-511053-22-00Karolinska University Hospital560
招募中
2 期
Protective effect of simvastatin on inflammatory factorIRCT20200421047152N3Iran University of Medical Sciences84
已完成
2 期
Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's DiseaseParkinson DiseaseNCT02787590University Hospital Plymouth NHS Trust235
进行中(未招募)
1 期
sing Simvastatin to improve immune responses in older people with pneumoniaEUCTR2012-003343-29-GBniversity of Birmingham56
